| Name | Title | Contact Details |
|---|
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
Ability Services Network Inc is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MyHealth Centre is a unique collaborative partnership of medical professionals and health care industry experts established in order to deliver quality and innovation in patient care. MyHealth Centre is a leading manager of independently owned diagnostic imaging facilities in Ontario. We currently manage over 25 Independent Health Facilities (IHFs) with agreements to develop additional IHF licenses.
EnduraCare Therapy Management is the largest privately held provider of rehabilitation services.
Allegiance Life is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.